A Randomized, Double-Blind Placebo Controlled Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2012
At a glance
- Drugs Esreboxetine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Jun 2012 Planned number of patients changed from 330 to 450 as reported by European Clinical Trials Database.
- 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.
- 16 Feb 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.